Hip Fracture Surgery in a Patient on Apixaban with Renal Impairment
An 82-year-old woman is admitted with a displaced left femoral neck fracture after a fall at home. Her medical history includes atrial fibrillation treated with apixaban 5 mg twice daily, chronic kidney disease stage 3b with an estimated glomerular filtration rate of 31 mL/min/1.73 m², hypertension, and mild cognitive impairment. The last dose of apixaban was taken 14 hours ago. Admission bloods show hemoglobin 102 g/L, platelets 180 × 10⁹/L, INR 1.1, and a normal activated partial thromboplastin time. She is in severe pain but hemodynamically stable. The orthopedic team wants to proceed with hemiarthroplasty within 6 hours because of pressure on theatre capacity and her frailty. The anesthesiologist is asked to choose between spinal anesthesia, general anesthesia, and delaying surgery. There is no reversal agent immediately available, and anti-Xa testing would take at least 8 hours.
1. What is the safest anesthetic plan for this patient, and how does apixaban's pharmacokinetics in renal impairment influence your decision?
Read the worked answer
Conclusion: Spinal anesthesia should not be performed at 14 hours after apixaban in a patient with an eGFR of 31 mL/min/1.73 m². If surgery cannot be delayed, general anesthesia is the safer choice.
Reasoning:
- Standard guidance for neuraxial anesthesia after apixaban is to withhold the drug for at least 72 hours when renal function is normal. Apixaban is partly renally cleared; with an eGFR below 50 mL/min/1.73 m², the half-life is prolonged and residual anticoagulant effect is more likely. Many centers therefore extend the hold to 96 hours or require a normal anti-Xa apixaban level before neuraxial blockade.
- Only 14 hours have elapsed, so a spinal or epidural would carry a meaningful risk of spinal or epidural hematoma with potential permanent paraplegia.
- The benefit of spinal anesthesia does not justify that catastrophic risk, especially when a general anesthetic can be delivered safely.
Practical plan:
- Explain the reasoning to the orthopedic team and document the risk discussion.
- If the patient can wait, delay surgery for at least 72–96 hours and consider anti-Xa testing before neuraxial anesthesia.
- If surgery must proceed within 6 hours, use general anesthesia with an arterial line, careful induction to avoid hypotension, active warming, and multimodal analgesia. A peripheral nerve block such as a fascia iliaca block can be used for analgesia if coagulation is acceptable, but it does not replace neuraxial anesthesia and still carries bleeding risk.
- Involve hematology and discuss the absence of immediate reversal; andexanet alfa is not available.
2. If general anesthesia is chosen, outline your intraoperative management and postoperative thromboprophylaxis plan.
Read the worked answer
Intraoperative management:
- Use standard monitoring plus an arterial line because of her age, hypertension, and the hemodynamic instability associated with hip fracture surgery.
- Induce with a hemodynamically stable technique, avoiding large boluses that cause hypotension. Maintain normothermia, because elderly patients lose heat rapidly and hypothermia worsens coagulopathy and cardiac stress.
- Use lung-protective ventilation, adequate analgesia, and antiemetic prophylaxis.
- Anticipate blood loss: ensure cross-matched blood is available, use tranexamic acid if there is no contraindication, and consider cell salvage.
- Avoid nitrous oxide and high volatile concentrations if she is frail; consider total intravenous anesthesia or low-dose volatile anesthesia with depth monitoring.
Postoperative thromboprophylaxis:
- Hip fracture surgery carries a high venous thromboembolism risk, but she is also at bleeding risk from recent apixaban.
- Restart pharmacologic prophylaxis only after surgical hemostasis is confirmed, usually 12–24 hours after surgery, and after discussion with hematology and orthopedics.
- Use mechanical prophylaxis immediately, mobilize early, and monitor for bleeding.
- Because she was anticoagulated before admission, do not simply restart the full therapeutic dose on day 1; individualize the timing and dose, and document the plan clearly.